Review anchor
Dipeptidyl peptidase 9
SINGLE PROTEIN · Bos taurus
As of 2026-09-13
Evidence Snapshot
Dipeptidyl peptidase 9
CHEMBL4295538
SINGLE PROTEIN
Bos taurus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dipeptidyl peptidase 9 as ChEMBL target CHEMBL4295538, mapped to UniProt E1BI31. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4295538
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
E1BI31
dipeptidyl-peptidase IV
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Dipeptidyl peptidase 9 matters
Dipeptidyl peptidase 9 is reviewed as dipeptidyl-peptidase IV (UniProt E1BI31); the current evidence base includes 1 approved drug, 7 compounds, and 1 assay, with lead potency reaching pChEMBL 6.5.
Protein context
dipeptidyl-peptidase IV
dipeptidyl-peptidase IV Sequence length is 877 aa.
Review this target as Dipeptidyl peptidase 9, mapped to UniProt E1BI31. ChEMBL maps the protein component as dipeptidyl-peptidase IV. Sequence length is 877 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt E1BI31
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 7 compounds, and 1 assay for this target. The dominant activity type is IC50. CHEMBL397070 is the current potency anchor at pChEMBL 6.5.
Use CHEMBL397070 as the tractability anchor when discussing potency (pChEMBL 6.5).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 6.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Dipeptidyl peptidase 9 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt E1BI31, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
7
Total Compounds
1
Total Assays
1
Approved Drugs
IC50: 7.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL397070
|
6.5 | IC50 | — |
|
|
No preferred name
CHEMBL142703
|
6.2 | IC50 | Approved |
|
|
No preferred name
CHEMBL98408
|
5.2 | IC50 | — |
|
|
No preferred name
CHEMBL383705
|
5.0 | IC50 | — |
|
|
No preferred name
CHEMBL98869
|
4.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
VILDAGLIPTIN
CHEMBL142703
|
2007 |
Source Header